The stock of Circassia Pharmaceuticals PLC (LON:CIR) is a huge mover today! The stock decreased 0.58% or GBX 0.5 on November 30, hitting GBX 85. About 80,266 shares traded hands. Circassia Pharmaceuticals PLC (LON:CIR) has declined 68.36% since April 29, 2016 and is downtrending. It has underperformed by 73.58% the S&P500.
The move comes after 7 months positive chart setup for the GBX 242.16M company. It was reported on Nov, 30 by Barchart.com. We have GBX 89.25 PT which if reached, will make LON:CIR worth GBX 12.11 million more.
Circassia Pharmaceuticals PLC (LON:CIR) Ratings Coverage
Out of 6 analysts covering Circassia Pharmaceuticals (LON:CIR), 5 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 83% are positive. Circassia Pharmaceuticals has been the topic of 26 analyst reports since October 27, 2015 according to StockzIntelligence Inc. Peel Hunt maintained the shares of CIR in a report on Wednesday, May 25 with “Buy” rating. The firm earned “Overweight” rating on Monday, March 14 by JP Morgan. As per Tuesday, September 27, the company rating was maintained by Peel Hunt. The company was maintained on Tuesday, October 27 by Peel Hunt. The rating was maintained by Numis Securities with “Buy” on Friday, March 11. The rating was maintained by Peel Hunt on Tuesday, April 19 with “Buy”. The company was maintained on Tuesday, February 23 by Peel Hunt. The firm has “Hold” rating by Cantor Fitzgerald given on Tuesday, September 27. The firm earned “Overweight” rating on Tuesday, June 21 by JP Morgan. As per Thursday, April 7, the company rating was maintained by Numis Securities.
More important recent Circassia Pharmaceuticals PLC (LON:CIR) news were published by: Fool.Co.Uk which released: “Can this week’s big fallers bounce back? Circassia Pharmaceuticals plc (-59 …” on June 23, 2016, also Fool.Co.Uk published article titled: “Are Royal Mail plc, AG Barr plc and Circassia Pharmaceuticals plc set to soar …”, Fool.Co.Uk published: “Why are Circassia Pharmaceuticals plc, Royal Bank of Scotland Group plc and …” on June 20, 2016. More interesting news about Circassia Pharmaceuticals PLC (LON:CIR) was released by: Fool.Co.Uk and their article: “Should You Buy Hikma Pharmaceuticals Plc, Circassia Pharmaceuticals PLC …” with publication date: July 28, 2015.
Circassia Pharmaceuticals plc is a specialty biopharmaceutical firm focused on allergy and respiratory diseases. The company has a market cap of 242.16 million GBP. The Firm operates through three divisions: Allergy, which relates to a range of immunotherapy development products for the treatment of allergy; NIOX, which relates to the portfolio of products used to improve asthma diagnosis and management by measuring fractional exhaled nitric oxide , and Respiratory, which relates to the portfolio of asthma and chronic obstructive pulmonary disease product candidates. It currently has negative earnings. The Company’s next-generation immunotherapy is in Phase III testing for cat allergy.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.